Medication evidence profile
Limaprost
Clinical overview
Limaprost has a public medication-list entry in Yamada-ABS 2023. This profile has one source version to examine, so a cross-scale comparison is not available from these rows.
Source-specific scores
| Source | Score |
|---|---|
| JARS | Not listed |
| Yamada-ABS | 1 |
| BAAS | Not listed |
| Swe-ABS | Not listed |
| GABS | Not listed |
| KABS | Not listed |
| CALS | Not listed |
How to read this: 0 means the source explicitly assigned zero. “Not listed” means the source did not provide a score for this medication. Scores from different scales are not averaged.
How to interpret the evidence
1 of 7 public source versions contain an explicit medication-list entry for Limaprost.
None of the public rows in this profile is an explicit zero. An unlisted source still supplies no value.
Source labels and provenance · 1 observation
- Yamada Pharmacological Anticholinergic Burden Scale 2023
Source label: Limaprost. Published value: 1.
Source version: YAMADA-ABS-2023
Source location: RC4 source recovery; recovery_scope=primary_nonzero_complete
Observation: YAMADA_ABS_2023_R0015; rating state: published_rating.
Dose, route, and formulation notes
Distinct v3 concept retained conservatively; do not collapse by substring or class similarity.
What this page does not establish
- No medication-list entry is available here from JARS 2025, BAAS 2019, Swe-ABS 2023, GABS 2018, KABS 2020 open validation supplement, and CALS 2022 Table 4. These gaps remain “Not listed”; no score is inferred from another source or from class membership.
- Use source-specific route/formulation where provided.
- These source records do not estimate an individual’s probability of harm or establish whether to start, stop or change a medication. Ordinal source scores are not averaged into a UnifiedACB score.
References
- Yamada S, Mochizuki M, Chimoto J, Futokoro R, Kagota S, Shinozuka K. Development of a pharmacological evidence-based anticholinergic burden scale for medications commonly used in older adults. Geriatr Gerontol Int. 2023;23(7):558-564. doi:10.1111/ggi.14619. Open source
Ask a follow-up
Go to your medication comparison · How UnifiedACB handles disagreement
Ask about this medication
Medication context: Limaprost
Ask about this medication